NCT03332095: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03332095 |
|---|---|
| Title | Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 2, 2018 |
| Completion date | Aug. 19, 2020 |
| Required reporting date | Aug. 19, 2021, midnight |
| Actual reporting date | Aug. 5, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |